Articles
| Open Access |
https://doi.org/10.55640/
EVALUATION OF THE APOPTOTIC EFFECT OF THE NATURAL COMPLEX “ASZAFIR” IN SYNERGY WITH DOXORUBICIN (COMBINATION MODEL)
Mamatova Iroda Yusupovna,Ulugbekova Gulruh Juraevna ,Mamajonov Zafar Abdujalilovich , Doctor of Medical Sciences, Head of the Department of Biological Chemistry, Andijan State Medical Institute, Andijan, Uzbekistan,Department of Anatomy and clinical anatomy, Andijan State Medical Institute, Andijan, Uzbekistan ,Department of Anatomy and clinical anatomy, Andijan State Medical Institute, Andijan, UzbekistanAbstract
This study aimed to evaluate the apoptotic effect of the natural phytocomplex AsZafIr in synergy with doxorubicin in seminoma cells. Under in vitro conditions, primary cells isolated from human testicular seminoma were treated separately and in combination with 1 μM doxorubicin and 0.005% AsZafIr. Apoptosis levels were determined using Annexin V-FITC/PI flow cytometry, and the combination effect was assessed by the Chou–Talalay combination index (CI).The results showed that the combination of doxorubicin and AsZafIr increased the total apoptosis rate by 1.8–2-fold compared to monotherapy groups, and the calculated combination index (CI = 0.78 ± 0.04) confirmed a clear synergistic effect. The proportion of necrotic cells remained minimal (≤4%), indicating the relative safety of the combination.
The bioactive compounds of the AsZafIr complex (rosmarinic acid, apigenin, luteolin, and chlorogenic acid) modulate purinergic signaling pathways (CD39/CD73/A₂A), thereby reducing immunosuppression in the tumor microenvironment and activating mitochondrial apoptotic pathways. In addition, the antioxidant activity of the complex reduced chemotherapy-induced toxicity and preserved intracellular stability.
In conclusion, the natural AsZafIr complex, when used in combination with doxorubicin, demonstrates strong synergistic apoptotic activity and may be recommended as a promising, relatively safe and effective adjuvant agent in integrative oncotherapy for seminoma and other tumor types.
Keywords
AsZafIr, doxorubicin, synergy, apoptosis, seminoma, phytocomplex, purinergic signaling, Annexin V/PI, Chou–Talalay model.
References
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17. Erratum in: CA Cancer J Clin. 2024 Mar-Apr;74(2):203. doi: 10.3322/caac.21830. PMID: 38230766.
Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011 Jul;21(7):440-6. doi: 10.1097/FPC.0b013e32833ffb56. PMID: 21048526; PMCID: PMC3116111.
Lin X, Wu G, Wang S, Huang J. Bibliometric and visual analysis of doxorubicin-induced cardiotoxicity. Front Pharmacol. 2023 Nov 9;14:1255158. doi: 10.3389/fphar.2023.1255158. PMID: 38026961; PMCID: PMC10665513.
Zhou H, Zhang M, Cao H, Du X, Zhang X, Wang J, Bi X. Research Progress on the Synergistic Anti-Tumor Effect of Natural Anti-Tumor Components of Chinese Herbal Medicine Combined with Chemotherapy Drugs. Pharmaceuticals (Basel). 2023 Dec 15;16(12):1734. doi: 10.3390/ph16121734. PMID: 38139860; PMCID: PMC10748242.
Almohammad Aljabr B, Zihlif M, Abu-Dahab R, Zalloum H. Effect of quercetin on doxorubicin cytotoxicity in sensitive and resistant human MCF7 breast cancer cell lines. Biomed Rep. 2024 Feb 5;20(4):58. doi: 10.3892/br.2024.1745. PMID: 38414625; PMCID: PMC10895388.
Article Statistics
Downloads
Copyright License
This work is licensed under a Creative Commons Attribution 4.0 International License.